IntegriGen · Orbit

IntegriGen

Developing a durable cell therapy treatment for Dystrophic Epidermolysis Bullosa

Boulder, Colorado, United StatesHealthTechPre-seedFounded 2026Updated Oct 19, 2026Website ↗

Strategic interests

See all

Capital

High Priority

Pre-Seed Round: $3M

Seeking $3M in pre-seed capital to advance our clinical indication and early development milestones.

About

IntegriGen is a cell therapy company focused on developing a durable, clinically available treatment for Dystrophic Epidermolysis Bullosa (DEB). We are advancing an autologous cell therapy approach targeting COL7, the collagen protein underlying DEB, to address a severe unmet need in rare genetic skin disease.

We are guided by a simple principle: Patients are our focus. Caretakers are our essential partners. These directives allow us to create value for our stakeholders.

Problem

Dystrophic Epidermolysis Bullosa (DEB), and its most severe form Recessive Dystrophic Epidermolysis Bullosa (RDEB), is a rare and devastating genetic disorder caused by mutations in the COL7A1 gene. Patients experience chronically fragile skin that blisters and wounds from the slightest trauma, leading to lifelong pain, repeated infections, and a dramatically reduced quality of life. Current treatments are largely palliative, and durable therapeutic options remain out of reach for most patients.

Solution

IntegriGen is pursuing an autologous cell therapy approach targeting COL7 restoration, with a clinical indication designed to address the root genetic cause of DEB/RDEB. By working with a patient's own cells and correcting the underlying COL7 deficiency, our approach aims to provide long-lasting skin integrity and meaningful relief for patients who currently have no durable treatment options.

Our vision

Our vision is a world where a clinically available, durable treatment for DEB/RDEB is accessible to every patient who needs it. IntegriGen aims to advance from clinical indication through to approved therapy, setting a new standard of care for COL7-related disorders and paving the way for broader gene therapy applications in rare skin diseases.